| 10 |
2021.04.06 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(혈액암 치료제) |
Aptabio Therapeutics Inc. |
| 9 |
2021.03.30 |
Outcomes of Annual Meeting of Shareholders |
Aptabio Therapeutics Inc. |
| 8 |
2021.03.24 |
Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 승인) |
Aptabio Therapeutics Inc. |
| 7 |
2021.03.22 |
Submission of Audit Report |
Aptabio Therapeutics Inc. |
| 6 |
2021.03.15 |
Reporting reasons for holding general shareholders' meeting on the most concentrated date |
Aptabio Therapeutics Inc. |
| 5 |
2021.03.03 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제) |
Aptabio Therapeutics Inc. |
| 4 |
2021.01.29 |
Resolutions for Convocation of General Meeting of Shareholders |
Aptabio Therapeutics Inc. |
| 3 |
2021.01.29 |
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) |
Aptabio Therapeutics Inc. |
| 2 |
2020.12.31 |
Material Management Information related to Judgment of Investment(COVID-19 치료제 APX-115의 US FDA 2상 임상시험 IND 신청) |
Aptabio Therapeutics Inc. |
| 1 |
2020.12.11 |
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제(Therapeutic Agent For Liver Disorder)) |
Aptabio Therapeutics Inc. |
